Overview
VYNE Q3 net loss decreases compared to last year
Company progressing with strategic review to maximize shareholder value
Outlook
VYNE is conducting a strategic review to explore options like partnerships or mergers
Company expects cash runway to last into the first half of 2027
VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold
Result Drivers
STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions
COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$169,000
Q3 Net Income
-$7.28 mln
Q3 EPS from Cont Ops
-$0.17
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34
Press Release: ID:nGNXbBrRvS
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
